https://orcid.org/0000-0002-4914-8052
Citations (9)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Valentine Grumberg, Christos Chouaïd, François-Emery Cotté, Baptiste Jouaneton, Ronan Jolivel, Anne-Françoise Gaudin, Dorothée Reynaud, Jean-Baptiste Assié & Isabelle Borget. (2022) Long-term hospital resource utilization and associated costs of care for patients initiating nivolumab in advanced non-small cell lung cancer in France. Journal of Medical Economics 25:1, pages 691-699.
Read now
Read now
Joo-Young Byun, Sun-Kyeong Park, Boon Peng Ng, Yi-Shao Liu, Chae-Rin Kim & Chanhyun Park. (2022) A systematic review of economic evaluations of tyrosine kinase inhibitors for non-small cell lung cancer (NSCLC). Expert Opinion on Pharmacotherapy 23:11, pages 1247-1257.
Read now
Read now
Articles from other publishers (7)
Mari Jones, Julia Lowin, Bernadette Sewell, Rachel Elizabeth Gemine, Sarah Elizabeth Rees, Kirsty Lanyon & Keir E. Lewis. (2023) The Economic Potential of Smoking Cessation Interventions at the Point of Diagnosis of Non–Small Cell Lung Cancer. Value in Health.
Crossref
Crossref
Javier De Castro, Amelia Insa, Roberto Collado-Borrell, Vicente Escudero-Vilaplana, Alex Martínez, Elena Fernandez, Ivana Sullivan, Natalia Arrabal, David Carcedo & Alba Manzaneque. (2023) Economic burden of locoregional and metastatic relapses in resectable early-stage non-small cell lung cancer in Spain. BMC Pulmonary Medicine 23:1.
Crossref
Crossref
Joo-Young Byun, Ju-Eun Lee, Yoon-Bo Shim, Jihyun Kim, Sun Young Lee, Bo Ra Shin, Na Ri Yoon, Mi-Hai Park & Eui-Kyung Lee. (2022) Economic Burden of Recurrence in Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer: A Retrospective Study Using Nationwide Claims Data of South Korea. Advances in Therapy 40:2, pages 550-567.
Crossref
Crossref
Laura Guarga, Noelia Paco, Emili Vela, Montse Clèries, Julieta Corral, Joaquim Delgadillo, Caridad Pontes & Josep Maria Borràs. (2022) Changes in Treatment Patterns and Costs for Lung Cancer Have Not Resulted in Relevant Improvements in Survival: A Population-Based Observational Study in Catalonia. Cancers 14:23, pages 5791.
Crossref
Crossref
Matteo Franchi, Giacomo Pellegrini & Giovanni Corrao. (2022) Effectiveness and Cost-Effectiveness Profile of Second-Line Treatments with Nivolumab, Pembrolizumab and Atezolizumab in Patients with Advanced Non-Small Cell Lung Cancer. Pharmaceuticals 15:4, pages 489.
Crossref
Crossref
Irfan Cicin, Ergun Oksuz, Nuri Karadurmus, Simten Malhan, Mahmut Gumus, Ulku Yilmaz, Levent Cansever, Halit Cinarka, Erdogan Cetinkaya, Murat Kiyik, Ahmet Ozet, Irfan Cicin, Ergun Oksuz, Nuri Karadurmus, Simten Malhan, Mahmut Gumus, Ulku Yilmaz, Levent Cansever, Halit Cinarka, Erdogan Cetinkaya, Murat Kiyik & Ahmet Ozet. (2021) Economic burden of lung cancer in Turkey: a cost of illness study from payer perspective. Health Economics Review 11:1.
Crossref
Crossref
Linxin Teng, Kaiyuan Wang, Weiping Chen, Yun-shan Wang & Lei Bi. (2020) HYR-2 plays an anti-lung cancer role by regulating PD-L1 and Akkermansia muciniphila. Pharmacological Research 160, pages 105086.
Crossref
Crossref